BioSpace News Archive

Delta-19 is designed to address the dual disease threats of Covid-19 and influenza with a superior approach for greater protection against both diseases.

Imago BioSciences, Inc. (“Imago”) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the closing of $134.4 million in gross proceeds from its previously announced initial public offering and $20.0 million in gross proceeds from its concurrent private placement.

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced operational progress and cash position (unaudited) for the second quarter of 2021.

Q-State Biosciences (“Q-State”), today announced it has been awarded a non-dilutive grant of $1.3 million from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the development of antisense oligonucleotide (ASO) therapeutics for the treatment of cancer pain

Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021.

Q2i, a provider of digital health technology, announced today that they have been granted NIH approval to move their Opioid Addiction Recovery Support – Contingency Management (OARS-CM) software application to a Phase II clinical trial.

NeurOptics, the leader in the science of pupillometry, today announced its NPi® Pupillometer and the Neurological Pupil index™ (NPi®) are now being used by Inova Health System, Northern Virginia’s leading nonprofit healthcare provider, as an essential tool for measuring pupil reactivity in patients with brain injury.

Owens & Minor, Inc. plans to release financial results for the second quarter of 2021 on Tuesday, August 3, 2021, before trading begins on the New York Stock Exchange.

Immuneering Corporation, a private biopharmaceutical company advancing a robust pipeline of oncology and neuroscience drug candidates that are designed to uniquely disrupt cellular signaling dynamics, announced the appointment of Michael Bookman to the newly created position of General Counsel and Secretary, effective immediately.

Pacific Biosciences of California, Inc., a leading provider of high-quality, long-read sequencing platforms, and Invitae Corporation, a leading medical genetics company, announced an intent to expand their multi-year collaboration to develop a production-scale high-throughput HiFi sequencing platform to include the sequencing technology developed by Omniome, Inc.